Aster Capital Management (Difc) LTD Crinetics Pharmaceuticals, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $441 Billion
- Q2 2025
A detailed history of Aster Capital Management (Difc) LTD transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 260 shares of CRNX stock, worth $11,551. This represents 0.0% of its overall portfolio holdings.
Number of Shares
260Holding current value
$11,551% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
236Shares Held
90MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$411 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$284 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$277 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$258 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$248 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.39B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...